Despite a lot of proposed therapeutic modalities have been tentatively suggested based on different pharmaceutic mechanisms, e.g., tolvaptan (i.e., vasopressin receptor blocker), somatostatin (i.e., growth hormone inhibitor) or mTOR inhibitor (such as sirolimus) [42, 43] for reducing the progression and complications of ADPKD, however, the consensus and practical evidence remained lacking to support the safety and effectiveness of these therapeutic agents. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.